The National Organization for the Reform of Marijuana Laws has filed a Notice of Intention to Participate in the Drug Enforcement Administration's administrative hearing set to begin June 29, 2026 - the proceeding that will formally consider whether marijuana moves from Schedule I to Schedule III under the Controlled Substances Act. NORML is seeking status as an "interested person," arguing that adult cannabis consumers, the constituency the organization has represented for more than fifty years, are directly affected by federal scheduling and remain unrepresented by any other likely participant. The organization does not oppose the removal of marijuana from Schedule I, but it is not conceding that Schedule III is the correct or final federal treatment.
Why Schedule III Leaves Adult-Use Operators in a Familiar Bind
For dispensary operators and multi-state cannabis businesses watching this process, the distinction NORML is drawing matters more than it might appear on the surface. Schedule III is a medicalized controlled-substance framework. It creates or expands pathways for FDA-regulated products, pharmaceutical research, and certain medical cannabis activities - but it does not map cleanly onto the adult-use markets that now operate under state law in a significant portion of the country.
Here's the catch: a Schedule III designation, if treated as the endpoint, would still leave adult-use consumers federally exposed. They are not patients. They are not seeking physician supervision or claiming medical necessity. They are purchasing products from licensed dispensaries operating under state-regulated adult-use systems - systems enacted by voters and legislatures - and none of that changes their federal legal status under a Schedule III framework. As NORML's filing puts it, "adult cannabis consumers do not become patients because federal law lacks a better category for them."
That unresolved gap has direct operational consequences. Dispensaries in adult-use states have built entire business models around state-compliant retail - age verification, seed-to-sale tracking through systems like METRC, compliant packaging, COA-backed product batches, point-of-sale systems wired for cannabis compliance. None of that infrastructure converts an adult-use transaction into a medically authorized one. A federal framework that only formally accounts for patients and researchers leaves licensed adult-use retailers selling product that remains, in federal terms, without a coherent legal home.
The 280E Shadow and What Rescheduling Does - and Doesn't - Fix
The conversation about rescheduling has never been just about symbolism. Cannabis businesses operating under Schedule I are denied standard federal business tax deductions under Section 280E of the Internal Revenue Code, which prohibits deductions for businesses trafficking in Schedule I or II controlled substances. Moving to Schedule III would remove that prohibition - and for operators running thin margins against high state excise taxes, local fees, and license costs, that tax relief would be material.
What rescheduling to Schedule III does not fix, though, is the broader regulatory incoherence NORML is pressing on. Banking access, for instance, remains constrained not only because of scheduling but because of the overall federal illegality of cannabis, the liability concerns of financial institutions, and the absence of a federal permitting structure for cannabis commerce. A Schedule III classification does not, by itself, create that structure. Neither does it resolve collateral consequences for consumers - employment drug testing, public housing eligibility, federal benefits - consequences that fall on adult-use consumers regardless of whether their state has legalized the activity.
NORML's filing addresses all of this. The organization also raises treaty obligations, illicit-market displacement, and the need for a complete hearing record that accounts for the tens of millions of adults participating in state-regulated adult-use systems. That last point is operationally relevant for anyone thinking about long-term market structure: a federal framework that medicalizes cannabis without addressing the adult-use market does nothing to bring illicit supply chains into compliance or support the licensed retail infrastructure that state programs have built.
The Hearing's Procedural History - and Why This Round May Be Different
This is not the first time DEA hearings have been scheduled in this proceeding. The administrative petition process began in October 2022 under the Biden administration. Hearings were scheduled previously but never took place, derailed by an interlocutory appeal. NORML filed to participate in those earlier hearings and was not among the parties selected.
In April of this year, the Justice Department terminated those proceedings and ordered new hearings, simultaneously directing that state-authorized medical cannabis products be reclassified under federal law from Schedule I to Schedule III. The new hearings are specifically scoped to consider "factual evidence and expert opinion" regarding the reclassification of all marijuana products - not only those authorized for medical use. That broader scope is precisely where NORML is inserting itself.
NORML's filing proposes testimony from founder and legal counsel R. Keith Stroup, Deputy Director Paul Armentano, and a witness with direct expertise in adult-use cannabis consumers and state-regulated adult-use systems. Whether the DEA selects NORML as a participant remains open - all filings are under review, and it is not yet known how many applicants will be chosen.
What This Means for Licensed Cannabis Businesses Now
Operators should read NORML's filing not as a consumer advocacy document sitting at the margins of the proceeding, but as a substantive legal and policy argument about what rescheduling actually resolves and what it leaves open. The organization is explicitly positioning itself as distinct from industry tax-relief groups and medical-only advocates - it is arguing that the hearing record will be structurally incomplete without testimony representing adult-use consumers as a category.
To put it plainly: if the DEA's hearing produces a record that centers medical use, pharmaceutical research, and tax implications while treating adult-use consumers as a side issue, the resulting rule will reflect that framing. For dispensary operators, wholesalers, cannabis brands, and compliance professionals who have built operations around adult-use retail, a federal rescheduling framework that fails to account for that market is not a solved problem - it is a deferred one.
NORML's long-stated position remains descheduling: removing marijuana from the CSA schedules entirely and replacing prohibition with a cannabis-specific federal regulatory structure built around public health, product testing, truthful labeling, youth prevention, responsible commercial conduct, and illicit-market displacement. Whether or not the organization secures a seat in the June 2026 hearing, that argument is now formally in the record.
